Company Description
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States.
The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.
Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation.
It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands.
The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors.
TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
| Country | United States |
| IPO Date | May 9, 2007 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Marlan D. Walker J.D. |
Contact Details
Address: 951 Yamato Road Boca Raton, Florida United States | |
| Website | https://www.therapeuticsmd.com |
Stock Details
| Ticker Symbol | TXMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000025743 |
| CUSIP Number | 88338N206 |
| ISIN Number | US88338N2062 |
| Employer ID | 87-0233535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marlan D. Walker J.D. | Chief Executive Officer |
| Douglas Steelman | Vice President of Market Access |
| Governor Thomas G. Thompson | Executive Chairman |
| Joseph A. Ziegler | Principal Financial & Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 05, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 25, 2024 | ARS | Filing |
| Oct 25, 2024 | DEFA14A | Filing |
| Oct 25, 2024 | DEF 14A | Filing |
| Sep 20, 2024 | 8-K | Current Report |
| Aug 26, 2024 | 4 | Filing |
| Aug 23, 2024 | 4 | Filing |